206 related articles for article (PubMed ID: 31874280)
41. Bisphosphonates: preclinical aspects and use in osteoporosis.
Fleisch HA
Ann Med; 1997 Feb; 29(1):55-62. PubMed ID: 9073324
[TBL] [Abstract][Full Text] [Related]
42. Mechanisms of action of bisphosphonates.
Rodan GA
Annu Rev Pharmacol Toxicol; 1998; 38():375-88. PubMed ID: 9597160
[TBL] [Abstract][Full Text] [Related]
43. The role of bisphosphonates in breast and prostate cancers.
Brown JE; Neville-Webbe H; Coleman RE
Endocr Relat Cancer; 2004 Jun; 11(2):207-24. PubMed ID: 15163299
[TBL] [Abstract][Full Text] [Related]
44. Bisphosphonates: new indications and methods of administration.
Reid IR
Curr Opin Rheumatol; 2003 Jul; 15(4):458-63. PubMed ID: 12819475
[TBL] [Abstract][Full Text] [Related]
45. Bisphosphonates as anticancer therapy for early breast cancer.
Mahtani R; Jahanzeb M
Clin Breast Cancer; 2010 Oct; 10(5):359-66. PubMed ID: 20920980
[TBL] [Abstract][Full Text] [Related]
46. Recent advances in liposome formulations for breast cancer therapeutics.
Yang B; Song BP; Shankar S; Guller A; Deng W
Cell Mol Life Sci; 2021 Jul; 78(13):5225-5243. PubMed ID: 33974093
[TBL] [Abstract][Full Text] [Related]
47. [Malignancy-associated hypercalcemia].
Oura S
Nihon Rinsho; 2003 Jun; 61(6):1006-9. PubMed ID: 12806951
[TBL] [Abstract][Full Text] [Related]
48. The evolving role of bisphosphonates.
Theriault RL; Hortobagyi GN
Semin Oncol; 2001 Jun; 28(3):284-90. PubMed ID: 11402438
[TBL] [Abstract][Full Text] [Related]
49. N⁴-[Alkyl-(hydroxyphosphono)phosphonate]-cytidine-new drugs covalently linking antimetabolites (5-FdU, araU or AZT) with bone-targeting bisphosphonates (alendronate or pamidronate).
Schott H; Goltz D; Schott TC; Jauch C; Schwendener RA
Bioorg Med Chem; 2011 Jun; 19(11):3520-6. PubMed ID: 21536448
[TBL] [Abstract][Full Text] [Related]
50. Optimising treatment of bone metastases by Aredia(TM) and Zometa(TM).
Coleman RE
Breast Cancer; 2000; 7(4):361-9. PubMed ID: 11114866
[TBL] [Abstract][Full Text] [Related]
51. Bisphosphonates in multiple myeloma: a network meta-analysis.
Mhaskar R; Redzepovic J; Wheatley K; Clark OA; Miladinovic B; Glasmacher A; Kumar A; Djulbegovic B
Cochrane Database Syst Rev; 2012 May; (5):CD003188. PubMed ID: 22592688
[TBL] [Abstract][Full Text] [Related]
52. Bisphosphonates in prostate carcinoma.
Adami S
Cancer; 1997 Oct; 80(8 Suppl):1674-9. PubMed ID: 9362435
[TBL] [Abstract][Full Text] [Related]
53. The crossover of bisphosphonates to cancer therapy.
Sun M; Iqbal J; Singh S; Sun L; Zaidi M
Ann N Y Acad Sci; 2010 Nov; 1211():107-12. PubMed ID: 21062299
[TBL] [Abstract][Full Text] [Related]
54. [Effects of four bisphosphonates on macrophage phagocytosis: quantitative measurement by flow cytometry using high-fluorescence particles and human monocytic cell line THP-1].
Imoto S; Saigo K; Bohgaki M; Matsumoto E; Goto M
Rinsho Byori; 2014 Jan; 62(1):23-30. PubMed ID: 24724423
[TBL] [Abstract][Full Text] [Related]
55. Relative binding affinities of bisphosphonates for human bone and relationship to antiresorptive efficacy.
Leu CT; Luegmayr E; Freedman LP; Rodan GA; Reszka AA
Bone; 2006 May; 38(5):628-36. PubMed ID: 16185944
[TBL] [Abstract][Full Text] [Related]
56. Self-assembly nanoparticles for the delivery of bisphosphonates into tumors.
Salzano G; Marra M; Porru M; Zappavigna S; Abbruzzese A; La Rotonda MI; Leonetti C; Caraglia M; De Rosa G
Int J Pharm; 2011 Jan; 403(1-2):292-7. PubMed ID: 21055454
[TBL] [Abstract][Full Text] [Related]
57. Inflammatory Effects of Nitrogen-Containing Bisphosphonates (N-BPs): Modulation by Non-N-BPs.
Shima K; Tsuchiya M; Oizumi T; Takano-Yamamoto T; Sugawara S; Endo Y
Biol Pharm Bull; 2017; 40(1):25-33. PubMed ID: 28049945
[TBL] [Abstract][Full Text] [Related]
58. Pharmacologically Inactive Bisphosphonates as an Alternative Strategy for Targeting Osteoclasts: In Vivo Assessment of 5-Fluorodeoxyuridine-Alendronate in a Preclinical Model of Breast Cancer Bone Metastases.
Schem C; Tower RJ; Kneissl P; Rambow AC; Campbell GM; Desel C; Damm T; Heilmann T; Fuchs S; Zuhayra M; Trauzold A; Glüer CC; Schott S; Tiwari S
J Bone Miner Res; 2017 Mar; 32(3):536-548. PubMed ID: 27714838
[TBL] [Abstract][Full Text] [Related]
59. Anticancer effect of bisphosphonates: new insights from clinical trials and preclinical evidence.
Daniele G; Giordano P; De Luca A; Piccirillo MC; Di Maio M; Del Giudice A; De Feo G; Bryce J; Lamura L; Vecchione A; Normanno N; Perrone F
Expert Rev Anticancer Ther; 2011 Feb; 11(2):299-307. PubMed ID: 21342047
[TBL] [Abstract][Full Text] [Related]
60. Development of Liposomal Formulation for Delivering Anticancer Drug to Breast Cancer Stem-Cell-Like Cells and its Pharmacokinetics in an Animal Model.
Ahmad A; Mondal SK; Mukhopadhyay D; Banerjee R; Alkharfy KM
Mol Pharm; 2016 Mar; 13(3):1081-8. PubMed ID: 26832839
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
